InovitroTM TTFields Lab Bench System from Novocure recently released several new funding opportunities.
Inovitro™ TTFields Lab Bench System from Novocure is a laboratory research system for use in preclinical research examining the effects of Tumor Treating Fields (TTFields) in cancer cell cultures. In addition to the grant, if your institution does not currently have access to the InovitroTM TTFields Lab Bench System, Novocure will provide this system to complete the research.
These two-year grants of $120,000 are designed to support the salary and benefits of a postdoctoral or clinical fellow while working on mentored research focused on the preclinical application and relevance of TTFields in cancer.
This three-year grant of $225,000 is designed to support junior faculty conducting innovative research focused on the preclinical application and relevance of TTFields in cancer.
The awards and fellowships are supported by the Amercian Association for Cancer Research (AACR) and Novocure.
The FY19 Defense Appropriation provides $15 million (M) to the Department of Defense Peer Reviewed Alzheimer’s Research Program (PRARP) to support research which addresses the long-term consequences of traumatic brain injury (TBI) as they pertain to Alzheimer’s disease (AD) and related dementias (ADRD). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.
The Office of Research and Graduate Education will be hosting an engaging session with the new Director of Corporate and Foundation Relations, Shelly Birdsong-Maddex. Shelly will join HSC faculty on behalf of the WVU Foundation to discuss partnerships and identifying funding opportunities beyond the traditional agencies.
Treating a stubborn blood disease that strikes children may come down to tweaking energy production in stem cells, suggests research out of West Virginia University.